UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
June 21, 2019
(Commission File No. 001-38475)
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
CAYMAN ISLANDS
(Jurisdiction of incorporation or organisation)
83 CLEMENCEAU AVENUE
#12-03 UE SQUARE
SINGAPORE 239920
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☒
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
| |
| |
ASLAN PHARMACEUTICALS LIMITED |
(Registrant) |
| |
By: | /s/ Kiran Kumar Asarpota |
Name: | Kiran Kumar Asarpota |
Title: | VP Finance |
Date: June 21, 2019
Announcement of the re-election results of Board of Directors (including independent directors)
| 1. | Date of occurrence of the change: 2019/06/21 |
| 2. | Appointment of or changed personnel: Directors and Independent directors |
| 3. | Title, name and resume of the replaced person – before: |
| | |
Title: | Name: | Resume: |
Chairman | Carl Firth | Ex-Chairman of the company |
Director | Alnair Investment | Representative of director: Jun Wu |
Director | BV Healthcare II Pte. Ltd. | Representative of director：Lim Chin Hwee Damien |
INED | Andrew James Howden | INED of the company |
INED | Chin-Feng Sun | INED of the company |
INED | Robert E. Hoffman | INED of the company |
| 4. | Title, name and resume of the replacement – after: |
| | |
Title: | Name: | Resume: |
Director | Carl Firth | new-elected director of the company |
Director | Alnair Investment | new-elected director of the company; representative of director – Jun Wu |
Director | BV Healthcare II Pte. Ltd. | new-elected director of the company; representative of director – Lim Chin Hwee Damien |
INED | Andrew James Howden | new-elected INED of the company |
INED | Chin-Feng Sun | new-elected INED of the company |
INED | Robert E. Hoffman | new-elected INED of the company |
| 5. | Type of change: expiry of term of office |
| 6. | Reason for the change: Re-election |
| 7. | Number of shares held by the new personnel at the time of appointment: |
| | |
Title: | Name: | Number of shares |
Director | Carl Firth | 0 shares * |
Director | Alnair Investment | 8,823,528 shares ** |
Director | BV Healthcare II Pte. Ltd. | 7,542,112 shares |
INED | Andrew James Howden | 439,510 shares |
INED | Chin-Feng Sun | 0 shares |
INED | Robert E. Hoffman | 0 shares |
| 8. | Original term: from 2016/04/15 to 2019/04/14 |
| 9. | Effective date of the new appointment: 2019/06/21 |
| 10. | Rate of turnover of directors of the same term: NA |
| 11. | Rate of turnover of supervisors of the same term: NA |
| 12. | Rate of turnover of independent directors of the same term: NA |
| 13. | Change in one-third or more of directors (“Yes” or “No”): Yes |
| 14. | Any other matters that need to be specified: |
* Director Carl Firth holds his shares under a company Kimba Capital and the total number of shares are 3,344,340.
** Director Alnair Investment holds shares under a company Shanghai Cenova and the total number of shares are 1,063,830.
